GT BIOPHARMA, INC. Number of Operating Segments
GT BIOPHARMA, INC. (GTBP) reported Number of Operating Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-08-14
- GT BIOPHARMA, INC. number of operating segments for the quarter ending 2026-03-31 was 1.00 Segment.
- GT BIOPHARMA, INC. number of operating segments for fiscal 2025 was 1.00 Segment.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 1.00 Segment 10-Q/A · filed 2026-03-06 | |||
| 2025-06-30 | 1.00 Segment 10-Q/A · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |